New anti-thrombotic drugs for stroke prevention

Matteo Nicola Dario Di Minno, Anna Russolillo, Marina Camera, Marta Brambilla, Angela de Gregorio, Elena Tremoli, Giovanni Di Minno

Research output: Contribution to journalArticle

Abstract

Ischemic stroke is the third most common cause of death and of long-term disability and exhibits a high recurrence rate. Therefore, appropriate primary and secondary prevention is mandatory. In non-cardioembolic stroke, in addition to lifestyle changes and to targeted treatments, current guidelines recommend antiplatelet treatment. In cardioembolic stroke, Vitamin K antagonists (VKAs) are recommended. Although a favorable risk/benefit ratio of both treatments has also been demonstrated in elderly patients, registry data emphasize that such interventions are often under-used, especially in patients with atrial fibrillation (AF). Furthermore, variability in the inter-individual response to drugs has been recognized as a leading cause of event recurrence. Thus, in addition to poor adherence, efficacy and safety issues appear to be involved in the recurrence rate of stroke. In this review, we report main Registries data on adherence to stroke prevention treatment schedule. We also discuss the major limitations of "traditional" antithrombotic drugs and report Phase III study results on safety and efficacy of new antiplatelet and anticoagulant drugs, with emphasis on stroke prevention.

Original languageEnglish
Pages (from-to)723-732
Number of pages10
JournalCurrent Vascular Pharmacology
Volume9
Issue number6
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Stroke
Pharmaceutical Preparations
Recurrence
Registries
Safety
Vitamin K
Platelet Aggregation Inhibitors
Primary Prevention
Therapeutics
Secondary Prevention
Anticoagulants
Atrial Fibrillation
Life Style
Cause of Death
Appointments and Schedules
Odds Ratio
Guidelines

Keywords

  • Compliance
  • New antithrombotic drugs
  • Recommendations
  • Stroke prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

New anti-thrombotic drugs for stroke prevention. / Di Minno, Matteo Nicola Dario; Russolillo, Anna; Camera, Marina; Brambilla, Marta; de Gregorio, Angela; Tremoli, Elena; Di Minno, Giovanni.

In: Current Vascular Pharmacology, Vol. 9, No. 6, 11.2011, p. 723-732.

Research output: Contribution to journalArticle

Di Minno, Matteo Nicola Dario ; Russolillo, Anna ; Camera, Marina ; Brambilla, Marta ; de Gregorio, Angela ; Tremoli, Elena ; Di Minno, Giovanni. / New anti-thrombotic drugs for stroke prevention. In: Current Vascular Pharmacology. 2011 ; Vol. 9, No. 6. pp. 723-732.
@article{6863d0e88ced44c2865620be278244e3,
title = "New anti-thrombotic drugs for stroke prevention",
abstract = "Ischemic stroke is the third most common cause of death and of long-term disability and exhibits a high recurrence rate. Therefore, appropriate primary and secondary prevention is mandatory. In non-cardioembolic stroke, in addition to lifestyle changes and to targeted treatments, current guidelines recommend antiplatelet treatment. In cardioembolic stroke, Vitamin K antagonists (VKAs) are recommended. Although a favorable risk/benefit ratio of both treatments has also been demonstrated in elderly patients, registry data emphasize that such interventions are often under-used, especially in patients with atrial fibrillation (AF). Furthermore, variability in the inter-individual response to drugs has been recognized as a leading cause of event recurrence. Thus, in addition to poor adherence, efficacy and safety issues appear to be involved in the recurrence rate of stroke. In this review, we report main Registries data on adherence to stroke prevention treatment schedule. We also discuss the major limitations of {"}traditional{"} antithrombotic drugs and report Phase III study results on safety and efficacy of new antiplatelet and anticoagulant drugs, with emphasis on stroke prevention.",
keywords = "Compliance, New antithrombotic drugs, Recommendations, Stroke prevention",
author = "{Di Minno}, {Matteo Nicola Dario} and Anna Russolillo and Marina Camera and Marta Brambilla and {de Gregorio}, Angela and Elena Tremoli and {Di Minno}, Giovanni",
year = "2011",
month = "11",
doi = "10.2174/157016111797484189",
language = "English",
volume = "9",
pages = "723--732",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - New anti-thrombotic drugs for stroke prevention

AU - Di Minno, Matteo Nicola Dario

AU - Russolillo, Anna

AU - Camera, Marina

AU - Brambilla, Marta

AU - de Gregorio, Angela

AU - Tremoli, Elena

AU - Di Minno, Giovanni

PY - 2011/11

Y1 - 2011/11

N2 - Ischemic stroke is the third most common cause of death and of long-term disability and exhibits a high recurrence rate. Therefore, appropriate primary and secondary prevention is mandatory. In non-cardioembolic stroke, in addition to lifestyle changes and to targeted treatments, current guidelines recommend antiplatelet treatment. In cardioembolic stroke, Vitamin K antagonists (VKAs) are recommended. Although a favorable risk/benefit ratio of both treatments has also been demonstrated in elderly patients, registry data emphasize that such interventions are often under-used, especially in patients with atrial fibrillation (AF). Furthermore, variability in the inter-individual response to drugs has been recognized as a leading cause of event recurrence. Thus, in addition to poor adherence, efficacy and safety issues appear to be involved in the recurrence rate of stroke. In this review, we report main Registries data on adherence to stroke prevention treatment schedule. We also discuss the major limitations of "traditional" antithrombotic drugs and report Phase III study results on safety and efficacy of new antiplatelet and anticoagulant drugs, with emphasis on stroke prevention.

AB - Ischemic stroke is the third most common cause of death and of long-term disability and exhibits a high recurrence rate. Therefore, appropriate primary and secondary prevention is mandatory. In non-cardioembolic stroke, in addition to lifestyle changes and to targeted treatments, current guidelines recommend antiplatelet treatment. In cardioembolic stroke, Vitamin K antagonists (VKAs) are recommended. Although a favorable risk/benefit ratio of both treatments has also been demonstrated in elderly patients, registry data emphasize that such interventions are often under-used, especially in patients with atrial fibrillation (AF). Furthermore, variability in the inter-individual response to drugs has been recognized as a leading cause of event recurrence. Thus, in addition to poor adherence, efficacy and safety issues appear to be involved in the recurrence rate of stroke. In this review, we report main Registries data on adherence to stroke prevention treatment schedule. We also discuss the major limitations of "traditional" antithrombotic drugs and report Phase III study results on safety and efficacy of new antiplatelet and anticoagulant drugs, with emphasis on stroke prevention.

KW - Compliance

KW - New antithrombotic drugs

KW - Recommendations

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=80054077520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054077520&partnerID=8YFLogxK

U2 - 10.2174/157016111797484189

DO - 10.2174/157016111797484189

M3 - Article

C2 - 21143164

AN - SCOPUS:80054077520

VL - 9

SP - 723

EP - 732

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 6

ER -